Repare Therapeutics Inc - Asset Resilience Ratio
Repare Therapeutics Inc (RPTX) has an Asset Resilience Ratio of 31.38% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Repare Therapeutics Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Repare Therapeutics Inc's Asset Resilience Ratio has changed over time. See RPTX net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Repare Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Repare Therapeutics Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $39.78 Million | 31.38% |
| Total Liquid Assets | $39.78 Million | 31.38% |
Asset Resilience Insights
- Very High Liquidity: Repare Therapeutics Inc maintains exceptional liquid asset reserves at 31.38% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Repare Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Repare Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Repare Therapeutics Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Repare Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 38.57% | $68.07 Million | $176.51 Million | -5.69pp |
| 2023-12-31 | 44.25% | $112.36 Million | $253.90 Million | -6.40pp |
| 2022-12-31 | 50.65% | $184.42 Million | $364.07 Million | +48.64pp |
| 2021-12-31 | 2.02% | $7.44 Million | $368.71 Million | -0.09pp |
| 2020-12-31 | 2.11% | $7.53 Million | $357.09 Million | -- |
About Repare Therapeutics Inc
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camo… Read more